貝達藥業(300558.SZ):公司無第三代ALK抑制劑的項目立項或開發
格隆匯5月24日丨貝達藥業(300558.SZ)在投資者互動平台表示,每個創新藥有其自身的臨牀數據特點。根據2022年12月恩沙替尼eXalt3全球多中心一線Ⅲ期臨牀研究公佈的亞裔人羣分析數據,恩沙替尼在亞裔人羣中具有突出的療效優勢。公司會以其差異化的數據優勢為支點,同時藉助恩沙替尼全線適應症已納入國家醫保的契機,努力提升市場份額。目前,公司無第三代ALK抑制劑的項目立項或開發。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.